Arylamide inhibitors of HIV-1 integrase

Journal of Medicinal Chemistry

Volumn 40, Issue 8, 1997, Pages 1186-1194

  Zhao, He ^b   Neamati, Nouri ^b   Mazumder, Abhijit ^b   Sunder, Sanjay ^b   Pommier, Yves ^b   Burke Jr , Terrence R ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(5,6 DIHYDROXY 2 NAPHTHALENECARBOXAMIDO)PROPANE; 1,3 BIS(6,7 HYDROXY 2 NAPHTHALENECARBOXAMIDO)PROPANE; 5,6 DIHYDROXY 2 NAPHTHOIC ACID; 5,6 DIHYDROXY 2 NAPHTHOIC ACID METHYL ESTER; 6,7 DIHYDROXY 2 NAPHTHOIC ACID; 6,7 DIHYDROXY 2 NAPHTHOIC ACID METHYL ESTER; CURCUMIN; ENZYME INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; QUERCETIN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; DIMERIZATION; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ESTERIFICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROXYLATION; STRUCTURE ACTIVITY RELATION;

CAFFEIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMIN; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; NF-KAPPA B; PHENYLETHYL ALCOHOL; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030936836     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960449w     Document Type: Article

References (22)

1. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
2. LaFemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of active human immunodeficiency virus type 1 integrase for productive infection of human T-lymphoid cells. J. Virol. 1992, 66.
3. Sakai, H.; Kawamura, M.; Sakuragi, J.; Sakuragi, S.; Shibata, R.; Ishimoto, A.; Ono, H.; Ueda, S.; Adachi, A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 1993, 7, 1169-1174.
4. Taddeo, B.; Haseltine, W. A.; Farnet, C. M. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J. Virol. 1994, 68, 8401-8405.
5. Engelman, A.; Englund, G.; Orenstein, J. M.; Martin, M. A.; Craigie, R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 1995, 69, 2729-2736.
6. Katz, R. A.; Merkel, G.; Kulkosky, J.; Leis, J.; Skalka, A. M. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 1990, 63, 87-95.
7. Craigie, R.; Mizuuchi, K.; Bushman, F. D.; Engleman, S. A. A rapid in vitro assay for HIV DNA integration. Nucleic Acid Res. 1991, 19, 2729-2734.
8. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethlyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
9. Burke, T. R.; Fesen, M. R.; Mazumder, A.; Wang, J.; Carothers, A. M.; Grunberger, D.; Driscoll, J.; Kohn, K.; Pommier, Y. Hydroxylated aromatic inhibitors of HIV-1 integrase. J. Med. Chem. 1995, 38, 4171-4178.
10. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995, 34, 15111-15122.
11. Eich, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M. R.; Mazumder, A.; Pommier, Y. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem. 1996, 39, 86-95.
12. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; Emini, E. A.; Hazuda, D. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob. Agents Chemother. 1995, 39, 320-324.
13. Stanwell, C.; Ye, B.; Yuspa, S. H.; Burke, T. R., Jr. Cell protein cross-linking by erbstatin and related compounds. Biochem. Pharmacol. 1996, 52, 475-480.
14. Khorana, M. L.; Pandit, S. Y.; Pishawikar, A. D. Antibacterial and antifungal properties of β-naphthol derivatives VI. J. Pharm. Sci. 1967, 56, 993-997.
15. Zee, C. K. Y.; Nyberg, W. H.; Cheng, C. C. Synthesis of 8,9-dialkoxy-substituted tetrahydrobenz[h]isoquinolines. J. Heterocycl. Chem. 1972, 9, 805-811.
16. Mazumder, A.; Raghavan, K.; Weinstein, J.; Kohn, K. W.; Pommier, Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem. Pharmacol. 1995, 49, 1165-1170.
17. Nicklaus, M. C.; Milne, G.; Burke, T. R. QSAR of Conformationally Flexible Molecules - Comparative Molecular Field Analysis of Protein-Tyrosine Kinase Inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 487-504.
18. Burke, T. R., Jr.; Lim, B.; Marquez, V. E.; Li, Z.-H.; Bolen, J. B.; Stefanova, I.; Horak, I. Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p561ck. J. Med. Chem. 1993, 36, 425-432.
19. Jenkins, T. M.; Engleman, A.; Ghirlando, R.; Craigie, R. A soluble active mutant of HIV-1 integrase. J. Biol. Chem. 1996, 271, 7712-7718.
20. Schwenk, E.; Papa, D. J. Org. Chem. 1945, 10, 232.
21. Gray, G. W.; Jones, B. The preparation of 4-and 5-n-alkoxy-1-naphthoic and 6-and 7-n-alkoxy-2-naphthoic acids. J. Chem. Soc. 1954, 678-683.
22. Anderson, W. K.; McPherson, J.; Rick, A. C. J. Med. Chem. 1984, 27, 1321.